Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dirozalkib (XZP-3621) in ALK-Positive NSCLC
NCT05482087Phase 2Unknown
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Sep 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dirozalkib in non-small cell lung cancer (NSCLC), sponsored by Xuanzhu Biopharmaceutical. Status: unknown.
02
Drugs
dirozalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05482087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05482087.